Glp-1
The key questions
Where they part ways, and how each answer holds up. An answer stands or falls on what it explains and how it survives criticism, not on who holds it.
A tint shows how one school of thought would answer these questions. The two views stay as they are.
-
Does regain after stopping show that obesity needs long-term drug treatment, or that the drugs create dependence without addressing causes?
Mainstream: Regain shows obesity is a chronic, relapsing condition that, like hypertension, needs continued treatment.
Alternative: Regain shows the drugs suppress a symptom while the food environment and diet remain the root cause, so prevention and diet change should come first.
The mainstream answer holds up better, for now. The alternative cannot show lifestyle programmes with durable results comparable to the drugs, and its use of the regain evidence fits the mainstream reading equally well.
How each answer holds up
What it explains
Mainstream: It accounts for regain after stopping, the cardiovascular events seen after discontinuation, and the similar pattern seen when other chronic-disease drugs are stopped.
Alternative: It accounts for why obesity rates rose with ultra-processed food and why the drugs do not lead to lasting change on their own.
What would prove it wrong
Mainstream: If people who stayed on treatment did no better than those who stopped, or if weight and risk stayed down after stopping, the answer would fail. Trials show regain after stopping. The discontinuation outcome data are observational and open to confounding.
Alternative: If diet-based programmes produced weight loss and cardiovascular benefit as large and durable as the drugs do, this would be supported. Such durable results at population scale have mostly not been observed.
Weak spot
Mainstream: The Italian discontinuation finding is observational. People who stop may differ in health, income or adherence, so it cannot show that stopping caused the extra events.
Alternative: It cites the same discontinuation data as proof of dependence, but those data fit the chronic-disease reading equally well. It also does not explain why diet-based approaches have so rarely kept weight off.
-
Are the safety risks of GLP-1 drugs modest and manageable, or under-appreciated, especially for mass use by relatively healthy people?
Mainstream: Risks are mostly gastrointestinal and manageable, with rare serious events such as the small NAION increase that monitoring can handle.
Alternative: Side effects are still emerging and underweighted, and use by healthier people needs a higher safety bar.
The mainstream answer holds up better, for now. The one confirmed signal is small in absolute terms, and the alternative gives no measured harm large enough to change the balance. The lack of long-term data in healthy users keeps the question partly open.
How each answer holds up
What it explains
Mainstream: It accounts for the trial and real-world safety data and the favourable cardiovascular and kidney outcomes.
Alternative: It accounts for the NAION warning, the gastroparesis claims and the fact that long-term data are limited.
What would prove it wrong
Mainstream: If large long-term surveillance showed serious harms, such as widespread gastroparesis or optic or pancreatic events, outweighing benefits in healthier users, the answer would fail. The NAION signal is small. Long-term data in low-risk users are still limited.
Alternative: If rates of gastroparesis and other harms in large controlled data stay close to background levels, the answer would fail. The NAION warning is real but small in absolute terms. Gastroparesis causation is still disputed.
Weak spot
Mainstream: Long-term safety in low-risk people is called an open issue, so 'modest' rests partly on trials in higher-risk groups. Rare harms such as muscle and bone loss are less well measured.
Alternative: Its main example, NAION, adds about 2.6 cases per 100,000 patient-years, which is small. Lawsuits show that claims were made, not that the drug caused the harm. The 'higher bar' has no stated threshold.
-
Is treating body size with drugs harmful medicalization that increases stigma, or appropriate treatment of a disease?
Mainstream: Obesity is a chronic disease that warrants long-term drug treatment.
Alternative: Treating size as a disease reinforces anti-fat bias, and weight is a poor proxy for health.
A question of values. Mainstream weighs the measurable health gains from treating weight more heavily, while the alternative weighs the risks of stigma, eating disorders and defining bodies as diseased more heavily.
-
Should policy focus on price and access for the drugs, or on upstream food and prevention policy?
Mainstream: Expand coverage and affordability while keeping the drugs alongside lifestyle support and clinical supervision.
Alternative: Negotiate prices, allow generics and public manufacturing, and invest in food policy rather than a population-wide drug habit.
Still open. Whether price negotiation and generics widen access without hurting supply, and whether food policy can measurably change obesity rates, has not yet been observed.
How each answer holds up
What it explains
Mainstream: It accounts for the proven benefits that go unused when people cannot pay or are denied coverage.
Alternative: It accounts for monopoly pricing, rationed coverage and the gray-market compounding that grew from scarcity.
What would show it failing
Mainstream: The policy fails if wider coverage leads to poor adherence or unaffordable budgets with no better outcomes. That could be corrected by adjusting criteria.
Alternative: The policy fails if price cuts do not widen use, or if food policy does not move obesity rates. Food policy has had little measured effect so far.
Weak spot
Mainstream: It does not say how budgets can cover a very large eligible population at current prices.
Alternative: The two alternative positions pull apart: the price camp wants more drug use, while the food camp wants less. The food-policy part has little evidence of effect at scale.
Where they agree
- GLP-1 receptor agonists such as semaglutide and tirzepatide lower blood glucose and cause substantial weight loss in trials.
- Weight is commonly regained after the drugs are stopped.
- Gastrointestinal side effects are common, and NAION (an optic nerve complication) now carries a regulatory warning of about 2.6 extra cases per 100,000 patient-years.
- Cost, insurance coverage and unequal access limit who actually gets these drugs.
Your verdict
Your badge
Read both sides to the end and earn a badge to share. Most people never open the other one.
- Mainstream
- Alternative
References
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
- Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 2023.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Perkovic V et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). New England Journal of Medicine, 2024.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 2018.
- Glucagon-like peptide-1 - Wikipedia
- GLP-1 Drugs (GLP-1 Agonist) - List of Brands & Generics
Want to take notes?
Create an account to take notes on any argument, follow topics, save your searches and download your results as a PDF.
Comments
No comments yet. Be the first to comment!